Combining WX390 and Toripalimab for advanced solid tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to evaluate the safety and preliminary efficacy of WX390 in combination with Toripalimab for patients with advanced solid tumors. It is an open-label, multicenter phase Ib/IIa trial where participants will undergo a 4-week screening period followed by 8 cycles of treatment. The study will assess the maximum tolerated dose and any dose-limiting toxicities, along with safety and efficacy evaluations conducted every treatment cycle. Participants will be monitored for 8 weeks after the last dose to gather comprehensive safety data.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* ≥18 years of age
* Histological or cytological confirmed advanced solid tumor, standard regimen failed or no standard regimen available
* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
* Life expectancy of more than 3 months
* At least one measurable lesion according to RECIST 1.1
* Adequate organ function，
* Signed and dated informed consent

Exclusion Criteria:

* Anti-cancer therapy within 30 days prior to the initiation of investigational treatment
* Major surgery within 30 days prior to the initiation of study treatment
* Received corticosteroids treatment or other immunodepressant within 2 weeks before the first dose of study treatment
* Toxicity from a previous anti-tumor treatment that does not return to Grade 0 or 1 (except for alopecia)
* Patients who are suffering active interstitial lung disease
* Evidence of ongoing or active serious infection
* History of human immunodeficiency virus (HIV) infection or active hepatitis B or C infection
* Inability to take medication orally
* Abuse of alcohol or drugs
* People with cognitive and psychological abnormality or with low compliance
* Pregnant or lactating women

Where it's running

• the first affiliated hospital of Jilin university
  Changchun, Jilin, China Recruiting

Study contacts

• Principal investigator: Yanhua Ding, PhD — the first affiliated hospital of Jilin university
• Study coordinator: Xiaoxue Zhu
• Email: 123999320@qq.com
• Phone: 0086431-88782222

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• AL8326 plus toripalimab for advanced solid tumors

  This study will test whether taking AL8326 tablets together with toripalimab is safe and helps adults with advanced or metastatic solid tumors who have progressed after or have no standard treatment options.

  Recruiting at 15 sites Phase 1/2 Advenchen Laboratories, LLC · Beijing, Beijing Municipality and 14 other locations · NCT07392736

• Combining STC-15 with Toripalimab for Advanced Cancers

  This study is testing whether combining a new cancer drug, STC-15, with toripalimab can help people with advanced cancers feel better and improve their treatment outcomes.

  Recruiting at 11 sites Phase 1/2 STORM Therapeutics LTD · San Francisco, California and 13 other locations · NCT06975293

• Using toripalimab for advanced solid tumors with specific genetic mutations

  This study is testing if toripalimab can help people with advanced solid tumors that have certain genetic mutations feel better and live longer.

  Recruiting at 4 sites Phase 2 Sun Yat-sen University · Guangzhou, Guangdong and 3 other locations · NCT03810339

• TMV vaccine alone or with toripalimab for recurrent head and neck cancer

  This study tests a personalized TMV vaccine, alone and with toripalimab, in adults whose head and neck cancer has returned and is planning salvage surgery.

  Recruiting Phase 1 Metaclipse Therapeutics Corporation · Houston, Texas · NCT07898124

• Toripalimab Plus Cetuximab and Irinotecan for second-line right-sided colon cancer

  This phase II study tests whether a combo of toripalimab, cetuximab, and irinotecan helps adults with second-line, right‑sided, RAS/BRAF wild-type advanced colon cancer.

  Recruiting Phase 2 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing, Beijing Municipality · NCT07896681

• Propranolol with Toripalimab and Platinum Chemo before/around surgery in NSCLC

  This study tests whether adding propranolol to toripalimab and platinum-based chemotherapy is safe and tolerable for people with resectable non-small cell lung cancer before surgery.

  Recruiting Phase 1 Second Xiangya Hospital of Central South University · Changsha, Hunan and 3 other locations · NCT07886229

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.